Antibody Testing Market Segmented By Serological Test Kit, Immunoglobulin Kits, Lateral Flow Assay Kits, Chemicals and Reagents, Consumables Products
Industry: Healthcare
Published Date: December-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 246
Report ID: PMRREP31930
Worldwide revenue from the antibody testing market stands at US$ 7.9 Bn in 2022, with the global market estimated to surge ahead at a CAGR of 7.6% to reach a valuation of US$ 17.7 Bn by the end of 2033.
| Attributes | Key Insights |
|---|---|
|
Antibody Testing Market Size (2022) |
US$ 7.9 Bn |
|
Projected Market Value (2033) |
US$ 17.7 Bn |
|
Global Market Growth Rate (2023-2033) |
7.6% CAGR |
|
Market Share of Top 5 Countries |
54.2% |
As assessed by Persistence Market Research, serological test kits are expected to hold a market value of US$ 3.1 Bn by 2023. Overall, antibody testing market sales account for approximately 33.9% revenue share in the global infectious disease diagnostics market, which was valued at around US$ 23.3 Bn in 2022.
The global market for antibody testing recorded a historic CAGR of 6.3% in the last 7 years from 2015 to 2022.
The desire to be autonomous is on the rise, and the diagnostics sector is not immune to this trend. Due to the increasing patient demand, home testing or self-testing has experienced significant rise in the last few years.
There are many indications for the home testing kits, including pregnancy, diabetes, cardiovascular disease, oncology, and more.
Due to their user-friendliness and availability through multiple distribution channels, such as online pharmacies or medicine stores, these self-testing home kits are becoming more and more popular.
Home testing kits are becoming more and more popular, and this is mostly due to people's increased awareness of the need of maintaining their health and of protecting their privacy based on their medical conditions.
The popularity of the practise has increased to the point where certain healthcare organisations and regulatory agencies have developed guidelines for the proper use of home testing kits in order to assist consumers.
Point-of-care testing tools have opened up a wide range of options in terms of the indications that can be diagnosed in settings other than a laboratory.
Point-of-care diagnostics and imaging tools are about to spur the growth of notions like telemedicine in the healthcare sector. For instance, a research in a Thai village demonstrated how primary health centres are employing POC testing as a first step to establish telemedicine connections with medical specialists.
Due to POC testing's several advantages over traditional lab-based testing, including its short turnaround times, low skill requirement, and excellent reproducibility, the market for antibody testing is about to undergo a significant transition.
Even in distant locations with inadequate healthcare infrastructure, testing kits will become more widely available due to the hassle-free usage and portability that come with these devices. This, together with the benefits already discussed, will propel the demand for antibody testing.
The global market is thus likely to show high growth over the coming years at a CAGR of 7.6% and reach a global market size of US$ 17.7 Bn by 2033.
“Development of Disease Specific Biomarkers, and Lab Automation”
The market for antibody-based testing has new prospects thanks to recent advancements in the development of disease biomarkers. For instance, technical advances in proteomics, genomics, and metabolomics assist researchers in fine-tuning cancer and its subtypes based on genetic flaws they carry. The expansion of the testing market will be fuelled by the diagnostics tools based on these biomarkers.
By designing a final test kit that is more beneficial in terms of accuracy, applicability, reactivity, affordability, required logistics, and ultimately, health outcomes, organisations can gain from the development of condition-specific biomarkers.
These discoveries have triggered the introduction of a wide assortment of indications for the use of antibody-based test kits.
The diagnostic laboratory serves as a hub for medical services, research, and development. The increased prevalence of chronic diseases, rising elderly population, and growing general population all contribute to the rising demand for tests. As a result, rapid outcomes are necessary without compromising quality, which calls for further laboratory automation.
According to estimates, 70% of healthcare decisions are influenced by diagnostic results, and as laboratory automation rises, test kit adoption will soar. Since contemporary antibody-based test kits also only need a limited number of samples to run the test, automated analysers, for instance, can be used with them.
Thus, the rapid immunoassays will become an essential part of automated laboratories in the future, thereby expanding their market.
“Regulatory Impositions and Limitations of Current Diagnostics”
To safeguard their citizens against subpar products, most governments establish controls on the pharmaceutical and medical device industries through specialised regulatory bodies in their respective nations. These restrictions impede the market's expansion by delaying the introduction of new products. Small market participants could find it challenging to adhere to these rules, making the regulatory process burdensome.
The prolonged trial periods for medical devices make the entire process exorbitant. Therefore, the regulatory frameworks should be designed in a way that guarantees the highest possible quality will be provided to the customers, while also taking into account the financial goals of the pharmaceutical and medical device firms.
Due to increasing patient demand for individualised care, personalised pharmaceuticals are the wave of the future for the healthcare sector. Novel diagnostic tools continue to be crucial in this situation since they would allow medical professionals to identify patient-specific traits, create individualised treatment plans, and ultimately enhance patients' quality of lives.
The simple diagnostic tests that are typically utilised in the diagnostic industry are supported by the current system of reimbursement, nonetheless. Due to their extensive development process, the most contemporary diagnostic kits do not uncover this kind of support system. Evidently, these shortcomings are restricting the growth of the testing market in general and the antibody testing market in particular.
Why is the U.S. Market Booming?
“Rising Disease Prevalence and Presence of Insurance Reimbursement”
The U.S. accounted for around 94.4% market share in the North America market in 2022, and a similar trend is expected over the forecast period. Increasing autoimmune disease cases and the resulting increase in demand for antibody tests, as well as government initiatives to raise public awareness of the advantages of health insurance programmes, are some of the key factors anticipated to propel the global market during the forecast period.
Will Germany Be a Lucrative Market for Antibody Testing Manufacturers?
“Emergence of COVID-19 and Government Support for Test Kits”
Germany held around 19.2% market share of the Europe market in 2022. With the emergence of the global COVID-19 pandemic, Germany initiated reimbursement for COVID-19 antibody tests. The National Association of Statutory Health Insurance Physicians (KBV) stated on May 7, 2020 that COVID-19 antibody testing would be compensated. This ensured test accessibility to all citizens, thus promoting adoption of antibody test kits within the country.
How is China Emerging as a Prominent Market for Antibody Testing?
“Expanding R&D Capabilities for Novel Product Launch Activities”
China held the largest market share of about 49.9% of the East Asia market in 2022. According to the Indian Council of Medical Research, China sent 500,000 rapid antibody testing kits to India in April 2020. (ICMR). Additionally, Chinese R&D firms are concentrating more on developing biospecific antibody tests whereas the majority of foreign firms are primarily concerned with anti-CD3 antibodies. The Chinese antibody testing market is expanding due to the discovery of innovative biospecific antibodies and a number of anticipated product launch events.
Which Product is Driving Growth of the Global Antibody Testing Market?
“Rapid Results and Ease of Diagnosis”
The serological test kits segment held around 35.8% share of the global market in 2022. The benefits of serology include its direct use by medical professionals, the quick turnaround of results, the potential for patient involvement, and the availability of a learning opportunity that enhances the teaching of disease pathogenesis. Owed to a large disease burden globally, the segment is expected to gain traction over the forecast period.
Which Indication Largely Utilizes the Antibody Tests Globally?
“Climate Change and Infectious Disease Spread”
Infectious diseases held a market share of around 21.9% in 2022. Antibodies serve as a sign of defence and typically aid in the prevention of diseases. An antibody test is a blood test used to identify antibodies produced by the body against a disease as a defence mechanism by the immune system against the foreign/unknown organism. These tests reveal details about the infection and track the spread of a disease.
The global risk of infectious diseases is increasing primarily due to climate change. With a high burden of proliferation and prevalence of infectious diseases, this indication is a major segment of focus within the global market, providing traction to the overall sales of the antibody testing kits, through the forecasted years.
Which End User Offers the Antibody Testing Market a Profitable Outlook?
“Development of Innovative Technologies”
Diagnostic laboratories held a larger share of about 34.8% with a market value of around US$ 2.8 Bn in 2022. The growth of this segment is owed to the rising investments in clinical and diagnostic research, rising prevalence of infectious diseases, and availability of reimbursements by regional governments. Healthcare specialists recognized that the development of breakthrough diagnostic techniques employing cutting-edge technologies is crucial to containing this unprecedented disaster, as governments all over the world were not ready for such a pandemic at the time the global infectious disease crisis began.
Trinity Biotech, a developer and producer of diagnostic products, acquired the Emergency Use Authorization (EUA) from the US FDA in August 2020 for their Covid-19 IgG ELISA antibody test. The market for antibody testing will experience increased demand as a result of all these advances.
Key players within the market are focusing on product innovation in terms of technological advancements. Major competitors are also focusing on product availability with different size dimensions, and market penetration through alternate sales channels. Institutional level research is performed for continuous product evolution, and this is a major trend being followed by industry leaders within the global market.
Key instances include:
| Attribute | Details |
|---|---|
|
Forecast Period |
2023-2033 |
|
Historical Data Available for |
2015-2022 |
|
Market Analysis |
USD Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
Product:
Indication:
End User:
Region:
To know more about delivery timeline for this report Contact Sales
The global market is currently valued at around US$ 7.9 Bn in 2022.
Sales of antibody testing market are set to witness a high growth at a CAGR of 7.6% and be valued at around US$ 17.7 Bn by 2033.
Demand for antibody testing market increased at a 6.3% CAGR from 2015 to 2022.
The U.S., Germany, China, U.K., and Japan account for most demand for antibody testing, currently holding around 54.2% market share.
The U.S. accounts for around 94.4% share of the North American market in 2022.
Latin America accounts for around 6.3% share of the global market in 2022.
China market held a share of about 49.9% in the East Asia market in 2022, while Japan accounts for around 36.3% share.
Germany held around 19.2% market share of the Europe market in 2022.
Brazil market is expected to grow at a 7.9% CAGR during the forecast period.
Indian market for antibody testing is set to expand at a 10.1% CAGR over the forecast period.
